IL17A and systemic lupus erythematosus: Such combination therapies could involve pairing IL-17 antagonists with other immunomodulators, including corticosteroids, antimalarials (e.g., hydroxychloroquine), or immunosuppressants (e.g., mycophenolate mofetil and cyclophosphamide) used in SLE treatment.